

Type 2 Diabetes Therapeutic and Drug Pipeline Review 2026

Global Type 2 Diabetes Drugs and Companies Pipeline Review 2017-2026

PUNE, INDIA, November 22, 2017 /EINPresswire.com/ -- Summary

While the global T2D market is crowded with inexpensive generics and marked by a pipeline filled with me-too drugs, expects this market to undergo substantial growth between 2016 and 2026, doubling over the forecast period. The main driver of this enormous expansion will be the dramatic increase in disease prevalence, which is attributable to increased life expectancy and an increasingly sedentary and stressful lifestyle. The second largest driver will be physicians' efforts to delay disease progression and reduce the costly burden of diabetic complications through the use of combination therapies and novel branded drugs.

GET SAMPLE REPORT @ <https://www.wiseguyreports.com/sample-request/2401034-pharmapoint-type-2-diabetes-global-drug-forecast-and-market-analysis-to-2026> □

Despite the large number of marketed therapies, the T2D market is still experiencing large unmet needs and therefore has a significant growth opportunity for new patent-protected products. Metformin (dimethylbiguanide) will remain the first-line therapy overall for T2D due to physicians' familiarity with it and the availability of long-term data, but the usage of sulfonylureas (SUs), another front-line therapy, continues to be replaced by novel therapies with improved side-effect profiles. The battle for second- or third-line therapy will involve DPP-4Is, GLP-1RAs, SGLT-Is, and other upcoming novel therapies. Of all the currently marketed classes, GLP-1RAs and SGLT-Is will experience the fastest growth due to their beneficial CV effects, weight-loss effects, and increasing ease of use.

Scope

- Overview of T2D, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
- Annualized T2D therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2016 and forecast for ten years to 2026.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the T2D therapeutics market.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and future market competition in the global T2D therapeutics market.

Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
- Develop business strategies by understanding the trends shaping and driving the global T2D therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global T2D therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the global T2D therapeutics market from 2016-2026.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Content: Key Points

1 Table of Contents 2

1.1 List of Tables 6

1.2 List of Figures 10

2 [Type 2 Diabetes](#) (T2D): Executive Summary 11

2.1 T2D Sales to Double Across 7MM 12

2.2 Multiple Opportunities Exist to Address Existing T2D Market Unmet Needs 14

2.3 The Arrival of Insulin Biosimilars and Abundance of “Me-Too” Drugs Illustrates Corporate Shift in Focus from Therapeutic Value Towards Competitive Pricing and Non-novel Agents that Confer Incremental Benefits 18

2.4 Glucagon-Like Peptide -1 Receptor Agonist Class Faces Intense Internal Competition, Largely Revolving Around Drugs’ Ability to Improve Patient Compliance/Ease of Administration and Cardiovascular Effects 19

2.5 Newest T2D Drug Class, Sodium-Glucose Cotransporter Inhibitors, Will Continue To Gain Significant Market Share Despite Concerns 19

2.6 What Do Physicians Think? 20

3 Introduction 23

3.1 Catalyst 23

3.2 Related Reports 24

4 Disease Overview 25

4.1 Etiology 25

4.2 Pathophysiology 27

- 4.3 Symptoms 29
- 4.4 Prognosis 31
- 4.5 Quality of Life 31
- 5 Epidemiology 31
- 5.1 Disease Background 32
- ...Continued

ACCESS REPORT @ <https://www.wiseguyreports.com/reports/2401034-pharmapoint-type-2-diabetes-global-drug-forecast-and-market-analysis-to-2026> □

Get in touch: □

LinkedIn: www.linkedin.com/company/4828928

Twitter: <https://twitter.com/WiseGuyReports> □

Facebook: <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Norah Trent

wiseguyreports

+1 646 845 9349 / +44 208 133 9349

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/417078046>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.